Ipsen
PharmaParis, France, France · Est. 1929 · 5,800 employees
Ipsen is a global biopharmaceutical company focused on innovative medicines in oncology, neuroscience, and rare diseases.
9
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
18
Indications↗
Distinct diseases across all programs
214
Clinical Trials↗
All sponsored trials (all statuses)
34
Orange Book Patents
Across 3 drugs with upcoming expirations
Pipeline
Pipeline Snapshot
By Phase
9 drugs in development
Approved1
Phase 32
Phase 25
Preclinical5
By Therapeutic Area
top 5
Oncology
538%
Neurology
431%
Gastroenterology
18%
Immunology
18%
Infectious Disease
18%
R&D Momentum
69/100
Pipeline Velocity
39/100
Trial Completion Rate
78/100
Pipeline Concentration
27/100
Pipeline Freshness
79/100
Strategic Signals
- ↗Active in Gastroenterology but thin pipeline — potential licensing opportunity
Activity
Recent Activity
Last 14 days
Jul 11, 2026
Completed
Noninterventional, Multicentre, Prospective, Cohort Study Assessing the Quality of Life and Hormonal Levels in Premenopausal Patients With Hormone Receptor-positive and HER2-negative Early Breast Cancer in Italy - ROSE Study
Jul 10, 2026
Completed
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport®) in Comparison With OnabotulinumtoxinA (Botox®) When Treating Adults With Upper Limb Spasticity
Jul 10, 2026
Completed
A Phase IIIb Randomised, Parallel-Group, Double-Blind, Placebo-Controlled, Two-Arm Study to Evaluate the Effect of Elafibranor 80 mg on Normalisation of Alkaline Phosphatase in Adult Participants With Primary Biliary Cholangitis (PBC) and Inadequate Response or Intolerance to Ursodeoxycholic Acid.
Jul 9, 2026
Active, not recruiting
A Prospective, Multicountry Study to Estimate the Incidence of and Provide a Best Practice Model for Monitoring the Development of Post-Stroke Spasticity
Jul 9, 2026
Recruiting
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults
Jul 9, 2026
Recruiting
A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo Controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants
Jul 3, 2026
Recruiting
A Phase III Randomised, Parallel-Group, Double-Blind, Placebo-Controlled, Two-Arm Study to Evaluate the Efficacy and Safety of Elafibranor 80 mg on Long-Term Clinical Outcomes in Adult Participants With Primary Biliary Cholangitis (PBC)
Jul 3, 2026
Active, not recruiting
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid
Jul 3, 2026
Recruiting
Odevixibat Pregnancy and Lactation Surveillance Program: A Post-marketing, Long-term, Observational, Descriptive Study to Assess the Risk of Pregnancy and Maternal Complications and Adverse Effects on the Developing Fetus, Neonate, and Infant Among Individuals Exposed to Odevixibat During Pregnancy and/or Lactation
Jul 3, 2026
Active, not recruiting
Analysis of the Effect of Odevixibat (A4250) Versus External Controls on Clinical Outcomes in Patients With PFIC (Odevixibat Versus External Control [OvEC]-PFIC)
Jul 3, 2026
Recruiting
Characterization of Progressive Familial Intrahepatic Cholestasis (PFIC)-Related Genes in Adult Patients With Idiopathic Recurrent and Chronic Cholestasis in Spain - REGENIC
Details
Company Info
Company Overview
$13.5B
Mkt Cap
$3.6B
Revenue
—
Cash
CEOKamel Chenaoui
Founded1929
Employees5,800
HQParis, France, France
Websiteipsen.com
LinkedInCompany Page
Therapeutic Focus
OncologyNeuroscienceGastroenterologyRare Diseases
Pipeline
Drug Pipeline
Therapeutic Area
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Gastroenterology(1 drug)
—
—
1
1
—
Gastroenterology(1 drug)
Immunology(1 drug)
—
—
—
1
—
Immunology(1 drug)
Infectious Disease(1 drug)
—
—
1
—
—
Infectious Disease(1 drug)
Neurology(4 drugs)
—
—
4
1
1
Neurology(4 drugs)
Oncology(5 drugs)
4
—
—
—
1
Oncology(5 drugs)
Unknown / Other(1 drug)
1
—
—
—
—
Unknown / Other(1 drug)
Regulatory
Regulatory Timeline
20051 event
FDAAug 30
INCRELEX — INCRELEX
Application BLA021839 (BLA)
20211 event
FDAJul 20
Bylvay — BYLVAY
Application NDA215498 (NDA)
20231 event
FDAAug 16
Sohonos — SOHONOS
Application NDA215559 (NDA)
20241 event
FDAJun 10
Iqirvo — IQIRVO
Application NDA218860 (NDA)
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)